National Cancer Institute (nci)

This study tests a drug called Briquilimab to see if it can make stem cell transplants safer for people with GATA2 deficiency, a genetic condition that weakens the immune system and raises the risk of serious infections and blood cancers. About 7 people aged 6 to 70 will receive …

This study looks at whether giving the HPV vaccine on a different schedule (a first shot followed by a booster years later) still protects against HPV, a virus that can cause several cancers. About 200 healthy 9-11 year old girls and boys are taking part. Researchers will measure…

This study tests a drug called adavosertib in 18 adults with advanced solid tumors that have a missing SETD2 gene. The drug works by blocking enzymes that cancer cells need to grow. The goal is to see if it can shrink or control tumors in people who have already tried other treat…

This study tested a drug called pazopanib in 171 people with carcinoid tumors that were getting worse. The goal was to see if pazopanib could slow tumor growth compared to a placebo. Participants were randomly assigned to receive either the drug or a placebo, and researchers meas…

This study tests whether adding a drug called decitabine before standard chemotherapy can help more people with acute myeloid leukemia (AML) achieve remission. About 178 adults with AML that is not the most treatable type will receive either a low or high dose of decitabine follo…

This early-phase study tests the safety and best dose of a three-drug combination (entinostat, nivolumab, and ipilimumab) in people with advanced solid tumors or HER2-negative breast cancer that has spread or cannot be removed. The goal is to see if this approach can help control…

This study tested two immunotherapy drugs, nivolumab and ipilimumab, in 143 people with advanced anal cancer that had spread and not responded to earlier treatments. The goal was to see if these drugs could shrink tumors or slow cancer growth by helping the immune system fight th…

This study tested whether taking lenalidomide (a drug that helps the immune system fight cancer) after a stem cell transplant could keep multiple myeloma from coming back longer than taking a placebo. About 460 people with active multiple myeloma took part. The goal was to see if…

This study tests an experimental drug called selumetinib in children and young adults (ages 3-18) with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be removed by surgery. The goal is to see if the drug can shrink the tumors or stop them from growing. Participa…

This study tests a drug called AZD1775 in people with advanced cancers that have a specific genetic change (BRCA1 or BRCA2 mutation). The drug blocks a protein that cancer cells may need to grow. Researchers want to see if the drug can shrink tumors or stop them from growing. Abo…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemoradiation improves survival for people with limited stage small cell lung cancer. About 544 participants will receive either chemoradiation alone or chemoradiation plus atezolizumab. The goal is …

This study tests whether the drugs olaparib and cediranib, alone or together, work better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has returned after initial treatment. About 579 women with platinum-sensitive cancer are particip…

This study tests a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) in people with a type of thyroid cancer that no longer responds to radioactive iodine and has worsened after one prior targeted therapy. The goal is to see if this combination can shrink or co…

This study tested two drugs, olaparib and ceralasertib, in 24 people with bile duct or other solid tumors that have an IDH mutation. The goal was to see if the combination could shrink tumors or stop them from growing. While no tumor shrinkage was seen, the study helps researcher…

This study tests a drug called binimetinib in 53 adults with advanced cancers (like solid tumors or lymphoma) that have a specific genetic change called an NRAS mutation. The drug blocks proteins that help cancer grow. The goal is to see if it can shrink tumors or stop them from …

This study tests a drug called nivolumab in 26 people with cervical cancer that has come back or spread. Nivolumab helps the immune system attack cancer cells. The main goals are to see if tumors shrink and to check for side effects.

This study tests a new drug called TRC102 (methoxyamine) combined with two standard chemotherapy drugs (cisplatin and pemetrexed) in people with advanced solid tumors or mesothelioma that has not responded to prior treatments. The goal is to see if TRC102 can make cancer cells mo…

This early-stage study tested a combination of three drugs (lenalidomide, ibrutinib, and rituximab) in 12 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that had returned or stopped responding to previous treatments. The main goal was to find t…

This study tested two different doses of imatinib and another drug called dasatinib in 406 people newly diagnosed with chronic myeloid leukemia (CML). The goal was to see which treatment better reduces cancer cells in the blood. Participants took one of the drugs daily, and docto…

This study looks at whether adding an oral drug (CC-486) to standard chemotherapy (R-miniCHOP) can help people aged 75 and older with newly diagnosed aggressive B-cell lymphomas live longer without their cancer returning. About 422 participants will receive either the standard tr…

This study compares two drug combinations—melphalan, prednisone, and thalidomide (MPT) versus melphalan, prednisone, and lenalidomide (MPR)—in 306 newly diagnosed multiple myeloma patients who cannot undergo high-dose therapy. The goal is to see which combination better delays ca…

This study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose tumors worsened after prior treatment will receive either cabozantinib or a placebo. The goal is to see …

This study tested a drug called sapanisertib in 17 people with advanced bladder cancer that has a specific change in the TSC1 or TSC2 gene. The drug works by blocking a protein that helps cancer cells grow. The goal was to see if the drug could shrink tumors and how well people t…

This study tests whether adding epoetin alfa to lenalidomide helps people with myelodysplastic syndrome (MDS) and anemia more than lenalidomide alone. About 247 adults with low- or intermediate-risk MDS and low red blood cell counts took part. The main goal was to see if the comb…

This study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults whose rare cancers (like certain sarcomas and brain tumors) have returned or not responded to treatment. These cancers lack specific genes (SMARCB1 or SMARCA4), making them hard to trea…

This early-phase study tests a new drug (AZD8186) combined with chemotherapy (docetaxel) in people with advanced solid tumors that have certain gene changes (PTEN or PIK3CB mutations). The main goals are to find the safest dose and understand side effects. About 23 adults whose c…

This study tests two drugs that lower or block male hormones to slow or shrink a rare type of salivary gland cancer that has spread or come back. About 21 people whose cancer has a specific protein (androgen receptor) will receive daily darolutamide pills plus leuprolide injectio…

This study aimed to see if combining two immunotherapy drugs (tiragolumab and atezolizumab) with targeted radiation could help people with a hard-to-treat type of metastatic colorectal cancer called microsatellite stable (MSS). The trial was designed for adults aged 18 and older …

This large phase III trial studies whether adding the targeted drug dasatinib to standard combination chemotherapy can better control high-risk B-acute lymphoblastic leukemia (B-ALL) in nearly 6,000 children and young adults. The study focuses on patients whose cancer has genetic…

This study tested a combination of two drugs—trametinib (a targeted therapy) and docetaxel (chemotherapy)—in 60 people with advanced KRAS-mutant non-small cell lung cancer whose disease had worsened after one or two prior treatments. The goal was to see if the combination could s…

This early-phase study tested a combination of two drugs, vorinostat and azacitidine, in 18 adults with nasopharyngeal cancer or nasal NK-T cell lymphoma that had come back or spread. The main goal was to find the safest dose and understand side effects. The study is now complete…

This study tested a drug called vismodegib in 45 people with advanced chondrosarcoma, a rare bone cancer that has spread and is hard to treat. The goal was to see if the drug could shrink tumors or stop them from growing for at least 6 months. The drug works by blocking a specifi…

This early-stage trial tests a drug called peposertib combined with radiation therapy for people with advanced head and neck cancer who cannot take the standard chemo drug cisplatin. The study aims to find the safest dose and see if the combination helps control the cancer. About…

This study tests whether combining three drugs (durvalumab, olaparib, and cediranib) can help women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based chemotherapy. About 120 participants will receive either one of the drug combinatio…

This study tests whether a targeted drug called selumetinib works as well as or better than standard chemotherapy (carboplatin/vincristine) for children and young adults (ages 2–21) with NF1-related low-grade gliomas. The goal is to control tumor growth and improve vision in thos…

This study is for adults with a specific type of acute lymphoblastic leukemia (ALL) that has a genetic change called BCR-ABL. The trial compares the usual treatment (steroids, a targeted drug called a TKI, and chemotherapy) with the same treatment plus an extra drug called blinat…

This study tests a two-step treatment for people with certain rare skin cancers and lymphomas that haven't responded to standard care. First, patients receive a virus-based drug (talimogene laherparepvec) injected into tumors. Then, they get the same virus plus an immunotherapy d…

This phase 2 trial tests whether the immunotherapy drug nivolumab can stop or slow the growth of IDH-mutant gliomas, a type of brain tumor. The study includes 62 adults whose tumors have a high number of mutations (hypermutator phenotype) or not. Participants receive nivolumab in…

This study looks at a rare, often fatal disease called KSHV-associated multicentric Castleman's disease (MCD). It aims to understand how the disease works and test several experimental treatments, including high-dose zidovudine, valganciclovir, bortezomib, rituximab, and interfer…

This study tests whether combining nilotinib (a kinase inhibitor) with paclitaxel (a chemotherapy drug) can shrink or slow the growth of advanced solid tumors that have worsened after prior taxane treatment. About 40 adults with various solid cancers will receive both drugs. The …

This study tests a drug called copanlisib in 22 adults with advanced solid tumors that have lost a protein called PTEN. The drug works by blocking certain enzymes that help cancer cells grow and survive. The main goal is to see if the tumors shrink or stop growing. This is a phas…

This study tests the drug trametinib in people with advanced cancers that have specific BRAF gene changes (mutations or fusions). Trametinib blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. The study …

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab after standard chemotherapy helps prevent triple-negative breast cancer from coming back. About 1,155 patients with residual cancer after chemo will receive either pembrolizumab or a placebo. The study m…

This study compares a new two-drug combination (olaparib and temozolomide) against standard chemotherapy options (trabectedin or pazopanib) for people with advanced uterine leiomyosarcoma that has continued to grow after initial chemotherapy. The goal is to see if the new combo c…

This study tested a drug called crizotinib in people with advanced cancers that have a specific genetic change called ALK rearrangement. The goal was to see if the drug could shrink tumors or stop them from growing. Only 5 patients took part, and the study is no longer recruiting…

This study tests whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy and radiation helps people with esophageal or gastroesophageal junction cancer. About 278 adults with stage II-IVA cancer will receive the combination before and after surg…

This study tests whether combining two drugs—cediranib and olaparib—can shrink or slow advanced solid tumors that have spread or can't be removed by surgery. It includes people with certain types of breast, lung, and pancreatic cancer. The goal is to see how well the combination …

This early-phase trial tests a three-drug combination (tazemetostat, topotecan, and pembrolizumab) in adults whose small cell lung cancer has returned after prior treatment. The goal is to find the safest dose and see if the combo can shrink or stabilize the cancer. About 18 part…

This study tests whether adding the drug veliparib to standard radiation and chemotherapy can help children and young adults with a fast-growing brain tumor called high-grade glioma. Veliparib blocks a protein that helps cancer cells fix their DNA, making them more likely to die …

This study looks at whether adding an immunotherapy drug (nivolumab) to the usual two-drug treatment (encorafenib and cetuximab) can better shrink or control tumors in people with advanced colorectal cancer that has a specific BRAF gene mutation. About 84 adults whose cancer has …

This study is for people with a fast-growing blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It tests a strong chemotherapy combination (Hyper-CVAD plus dasatinib) and whether adding a donor stem cell transplant helps keep the cancer a…

This study tests a drug called copanlisib in people whose advanced cancer has a specific genetic change (PIK3CA mutation). The drug blocks a protein that helps cancer cells grow. Researchers want to see if it can shrink tumors or stop them from growing. About 35 adults with vario…

This study tests a combination of three hormone-blocking drugs (abiraterone, enzalutamide, and standard hormone therapy) given before surgery to men with newly diagnosed prostate cancer that hasn't spread. Researchers also use special PET/CT scans with a new tracer to better see …

This study tests two immunotherapy drugs, atezolizumab and tiragolumab, together in people with rare solid tumors that have spread or stopped responding to standard treatments. The goal is to see if the combination can shrink tumors and boost the body's immune attack on cancer. R…

This study tests a new combination of three drugs (tazemetostat, dabrafenib, and trametinib) in people with advanced melanoma that has a BRAF mutation and has stopped responding to standard treatment. The goal is to find the best dose and see if the combo can help control the can…

This study tested whether two immunotherapy drugs, nivolumab and ipilimumab, can shrink tumors in people with many different types of rare cancers. About 818 adults with rare solid tumors that had not responded to standard treatment took part. The goal was to see if this drug com…

This study tested three different drug combinations in 349 people with advanced (stage III or IV) or recurrent endometrial cancer. The goal was to see which combination worked best to stop the cancer from growing or spreading. Participants received either paclitaxel/carboplatin/b…

This study tests whether a mix of three immunotherapy drugs can shrink tumors in people with advanced HPV-related cancers, such as cervical, anal, and throat cancers. About 51 adults with cancer that has spread or cannot be removed will receive the drugs for up to one year. The g…

This early-phase study tests a drug called veliparib combined with two standard chemotherapies (carboplatin and paclitaxel) in people with advanced solid tumors that also have liver or kidney problems. The goal is to find the safest dose and understand how the body processes the …

This early-phase study tests a drug called berzosertib combined with whole brain radiation in 15 people with lung cancer that has spread to the brain. The main goal is to find the safest dose and watch for side effects. Researchers also track memory changes and quality of life. T…

This study tests whether adding olaparib to the standard chemotherapy drug temozolomide helps control advanced pheochromocytoma and paraganglioma—rare tumors that often spread or can't be removed. About 46 adults with these cancers will be randomly assigned to receive temozolomid…

This study tests a new oral drug called alvelestat for people who develop a serious lung condition (bronchiolitis obliterans syndrome) after a stem cell transplant. The drug aims to block a harmful enzyme that may damage the lungs. About 14 adults with chronic graft-versus-host d…

This study looked at 125 people with advanced non-small cell lung cancer that does not have a common gene mutation (EGFR). It tested two drugs, erlotinib and cabozantinib, given alone or together as a second or third treatment option. The goal was to see if the combination works …

This early-phase study tested an oral drug called triapine added to standard chemoradiation (cisplatin and radiation) for people with advanced cervical or vaginal cancer. The goal was to find the safest dose and check how well the body absorbs the drug. 21 participants were enrol…

This early-stage trial tests a combination of two immune-boosting drugs, pembrolizumab and recombinant interleukin-12, in 36 adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and check for side effects.…

This study looks at whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent serious side effects like graft-versus-host disease (GVHD) while still controlling blood cancers. About 105 people aged 15-65 with leukemia, lymphoma, or multipl…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) achieve a deeper remission. About 49 adults with AML, including those whose leukemia arose from prior conditions, will rece…

This study compares three different drug combinations for people with ovarian, fallopian tube, or primary peritoneal cancer that came back after platinum chemotherapy. The drugs include a standard chemo (Doxil), an immunotherapy (atezolizumab), and a targeted therapy (bevacizumab…

This study tests whether the immunotherapy drug pembrolizumab, given after surgery to remove Merkel cell cancer, can keep the cancer from returning better than just watching and waiting. About 280 adults with stage I to III Merkel cell cancer that was fully removed will take part…

This study looks at whether combining two targeted drugs (cediranib and olaparib) works better than either drug alone or standard chemo for women with ovarian, fallopian tube, or peritoneal cancer that has come back or kept growing after platinum-based chemo. About 582 women took…

This study tests whether adding the immunotherapy drug blinatumomab to standard chemotherapy helps adults with a certain type of leukemia (BCR-ABL-negative B-ALL) live longer or stay in remission longer. About 488 newly diagnosed patients took part. The goal is to see if the comb…

This study tests whether adding the drug pomalidomide to standard chemotherapy can improve outcomes for people newly diagnosed with a specific type of acute myeloid leukemia (AML) linked to prior blood disorders. About 50 adults will be randomly assigned to receive either the sta…

This study tests a three-part treatment for people with advanced solid tumors or bile duct cancers that have spread or can't be removed. It combines a targeted drug (peposertib), an immunotherapy (avelumab), and a short course of high-dose radiation. The goal is to find the safes…

This study tests whether adding an immunotherapy drug (nivolumab) to standard chemotherapy (paclitaxel) can better shrink or control a rare cancer of blood vessels called angiosarcoma. It involves 89 patients whose cancer cannot be cured by surgery or who declined surgery. Some p…

This study tests a drug called ulixertinib in children and young adults whose advanced cancers (solid tumors, lymphoma, or histiocytic disorders) have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or slow the cancer. About 20 participant…

This study tested whether adding the drug cixutumumab to standard chemotherapy (paclitaxel) helps people with advanced esophageal or stomach cancer that has spread. About 94 adults took part. The goal was to see if the combination could slow cancer growth longer than chemotherapy…

This early-stage study tested a combination of drugs (lenalidomide, dinutuximab, and sometimes isotretinoin) in 27 children and young adults with neuroblastoma that didn't respond to treatment or came back. The main goal was to find the safest dose and check side effects. Researc…

This study tests whether a very low dose of the drug apalutamide, taken for 3-4 weeks before prostate removal surgery, can lower PSA levels in men with early-stage prostate cancer. The goal is to see if such a low dose is effective enough to potentially allow men to delay or avoi…

This study tests a new drug (selinexor) added to standard chemotherapy (temozolomide) for people with a type of brain cancer called glioblastoma that has returned after initial treatment. The goal is to see if the combination is safe and works better than chemotherapy alone at sh…

This study is for children and young adults (ages 1 to 21) with advanced cancers that have come back or are not responding to treatment and have a specific change in their FGFR genes. The drug erdafitinib is given to block signals that help these cancer cells grow. The main goal …

This study tested a drug called ibrutinib in 18 people with stage IV melanoma that had not responded to previous treatments. The goal was to see if the drug could shrink tumors or slow the cancer's growth. Ibrutinib works by blocking certain enzymes that cancer cells need to grow…

This phase 3 trial tests whether adding bortezomib to a standard two-drug regimen (lenalidomide and dexamethasone) works better for people newly diagnosed with multiple myeloma who are not planning an immediate stem cell transplant. The study enrolled 525 participants and compare…

This study tests whether adding two immunotherapy drugs (atezolizumab and bevacizumab) to standard chemotherapy works better than chemotherapy plus just one immunotherapy drug for people with a rare, advanced liver cancer that cannot be surgically removed. About 88 adults with th…

This study compares the immunotherapy drug atezolizumab alone versus atezolizumab plus chemotherapy in patients with a specific genetic subtype of stomach or gastroesophageal junction cancer (MSI-H/dMMR). The goal is to see which approach better controls tumor growth before and a…

This study tests whether the drug atezolizumab, alone or with bevacizumab, can shrink tumors in people with a rare soft tissue cancer called alveolar soft part sarcoma that has spread or cannot be removed by surgery. Atezolizumab helps the immune system attack cancer cells, while…

This study tests whether adding the drug cediranib to standard chemotherapy (cisplatin and pemetrexed) helps people with malignant pleural mesothelioma, a rare cancer of the lung lining. The trial first finds the safest dose of cediranib, then randomly assigns patients to receive…

This early-stage trial tests the safety and best dose of the drug trametinib when given with or without whole-brain radiation for people with cancer that has spread to the brain. The drug blocks certain enzymes that help cancer cells grow, and radiation uses high-energy X-rays to…

This study tests whether a daily pill called obeticholic acid (OCA) can safely reduce the number of polyps in the small bowel and colon of people with familial adenomatous polyposis (FAP), a rare inherited condition that greatly raises the risk of intestinal cancer. About 80 adul…

This study tests a combination of three drugs (ipilimumab, nivolumab, and brentuximab vedotin) in people with Hodgkin lymphoma that has come back or not responded to prior treatment. The goal is to find the safest dose and see how well the drugs work together to shrink tumors. Ab…

This study tests whether taking two targeted drugs (dabrafenib and trametinib) after radiation therapy can help children and young adults with a specific type of aggressive brain cancer (BRAF V600-mutant high-grade glioma). About 58 participants aged 25 or younger will receive th…

This study tests whether adding the immunotherapy drug blinatumomab to standard chemotherapy or to dasatinib and prednisone can help older adults (65+) with acute lymphoblastic leukemia (ALL) live longer and control the disease. About 53 participants received treatment to see how…

This early-stage study tests the safety and best dose of two drugs—ibrutinib and lenalidomide—given together to people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The goal is to find a dose that controls the cancer with manageable side …

This study was designed to test whether combining two immunotherapy drugs, nivolumab and ipilimumab, could help children, teens, and young adults whose cancers had returned or stopped responding to treatment. It focused on tumors with many genetic mutations, which may respond bet…

This study tests whether adding the drug ganitumab to standard chemotherapy helps people with newly diagnosed Ewing sarcoma that has spread. About 312 participants will receive either chemo alone or chemo plus ganitumab. The goal is to see if the combination delays cancer growth …

This study tests whether adding an immunotherapy drug (atezolizumab) to standard radiation therapy helps people with early-stage non-small cell lung cancer live longer. About 480 participants with stage I-IIA lung cancer will receive either radiation alone or radiation plus atezo…

This study tests a new combination of two drugs (tocilizumab and atezolizumab) plus precise radiation for people whose glioblastoma brain tumor has come back. The goal is to change the tumor's environment so the immune system can attack it more effectively. About 59 adults will t…

This early-phase trial tests a new combination of three drugs for adults with newly diagnosed acute myeloid leukemia (AML) who cannot receive standard chemotherapy. The drugs include a targeted radiation therapy (lintuzumab-Ac-225), a BCL-2 inhibitor (venetoclax), and a hypomethy…

This study tests whether adding a drug called uproleselan to standard chemotherapy helps older adults with acute myeloid leukemia (AML) live longer without the cancer returning. About 267 participants receive either chemo alone or chemo plus uproleselan. The goal is to see if the…

This study tests whether the drug pazopanib can delay or prevent kidney cancer from returning in patients who have had surgery to remove all visible tumors. About 129 adults with advanced kidney cancer that has spread but was fully removed by surgery will receive either pazopanib…

This study tests whether adding cediranib to olaparib works better than olaparib alone for men with metastatic castration-resistant prostate cancer. Olaparib blocks a protein that helps cancer cells repair themselves, while cediranib stops tumor growth by blocking certain enzymes…

This study tests whether adding a drug called veliparib to standard chemotherapy (FOLFIRI) helps people with metastatic pancreatic cancer live longer. About 123 patients whose cancer returned after initial treatment will be randomly assigned to receive either FOLFIRI alone or FOL…

This study compares two experimental treatments—cabozantinib alone or combined with nivolumab—against standard chemotherapy for people with advanced non-squamous non-small cell lung cancer that has returned or spread. The goal is to see if these new options can slow cancer growth…

This study tested two different sequences of drugs in 267 people with advanced melanoma that has a BRAF mutation and cannot be removed by surgery. One group started with immunotherapy (ipilimumab and nivolumab) followed by targeted therapy (dabrafenib and trametinib); the other g…

This early-phase trial tests a new two-drug combination (sapanisertib plus osimertinib) in about 36 adults with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to osimertinib alone. The main goal is to find the safest dose and identify side effects. Th…

This study tests the drug crizotinib in people with advanced or hard-to-treat cancers that have a specific genetic change called MET exon 14 deletion. Crizotinib blocks signals that help cancer cells grow and spread. About 20 participants will receive the drug to see if their tum…

This phase 2 trial tests whether adding venetoclax to ASTX727 (decitabine + cedazuridine) works better than ASTX727 alone for people with chronic myelomonocytic leukemia or related blood cancers that have too many immature cells (blasts). About 132 adults with these rare bone mar…

This study tests whether women can collect their own vaginal samples for HPV testing as accurately as a doctor can during a pelvic exam. It involves 750 participants referred for colposcopy or cervical procedures. The goal is to see if self-collection is a reliable, more comforta…

This study tests whether a new radioactive tracer called 18F-DCFPyL can better detect prostate cancer that has spread compared to a standard tracer. About 96 adults with metastatic prostate cancer will receive both types of PET/CT scans. Researchers will check how accurate the ne…

This study tests a combination of two experimental vaccines (Tri-Ad5 and N-803) to see if they can prevent colon cancer and other cancers in people with Lynch syndrome, a genetic condition that raises cancer risk. The vaccines train the immune system to recognize and destroy prec…

This study tests whether metformin, a standard diabetes medicine, can prevent oral cancer in people who have precancerous mouth patches (leukoplakia or erythroplakia). Twenty-six adults with these lesions took metformin to see if the patches shrank or disappeared. The goal is to …

This study tests whether a single dose of the HPV vaccine can protect young women aged 18-30 from cervical cancer. Researchers in Costa Rica are giving 5,000 participants either one dose of HPV vaccine or a placebo to see if it reduces persistent HPV infections. If successful, it…

This study looks at whether taking aspirin on an intermittent schedule can help prevent colorectal cancer in people who have had colorectal adenomas (precancerous growths). The trial involves 81 participants and measures changes in cell growth and death markers in the colon linin…

This study collects blood, cheek cells, semen, urine, or nail clippings from up to 1,200 healthy adult volunteers at NCI-Frederick. The samples are used for lab research only, such as genetic studies, immune tests, and drug development. Donors are paid for their time and are not …

This study collects blood, urine, and tumor samples from 500 adults with breast, ovarian, or uterine cancer, plus some of their relatives. The goal is to create a tissue repository for future research into DNA changes that drive these cancers. Participants give samples during rou…

This study gathers white blood cells and tumor samples from up to 7,000 cancer patients and healthy volunteers to help scientists grow powerful anti-cancer cells in the lab. The cells are used to create experimental treatments for cancers like melanoma, lung, and breast cancer. P…

This study collects blood samples from people who have unexpected or severe side effects from drugs they are taking in other NIH trials. The goal is to measure drug levels in the blood to better understand why side effects happen in some people but not others. Up to 100 participa…

This study follows 259 children and adults with NF1 for up to 10 years to learn how the disease changes over time. Researchers track tumors, symptoms, and quality of life through regular checkups, scans, and tests. The goal is to better understand NF1 and help design future treat…

This study looks at whether combining a genomic test (Oncotype DX GPS) with MRI scans can better identify men with prostate cancer who are good candidates for focal therapy—a treatment that targets only the cancerous areas, sparing healthy tissue. Researchers will analyze stored …

This study collects leftover tissue and blood samples from 1,200 adults with known or suspected cancer during their standard surgeries or biopsies. Researchers will compare these samples to normal tissue to find differences that could lead to new cancer treatments. No extra proce…